The presence of primary cilia in cancer cells does not predict responsiveness to modulation of smoothened activity

Spann,Ashley  L.; Yuan,Kun; Goliwas,Kayla  F.; Steg,Adam  D.; Kaushik,Devanshu  D.; Kwon,Yeon-Jin; Frost,Andra  R.

doi:10.3892/ijo.2015.3006

The presence of primary cilia in cancer cells does not predict responsiveness to modulation of smoothened activity

Authors:
- Ashley L. Spann
- Kun Yuan
- Kayla F. Goliwas
- Adam D. Steg
- Devanshu D. Kaushik
- Yeon-Jin Kwon
- Andra R. Frost
View Affiliations

Affiliations: Department of Pathology, University of Alabama at Birmingham, Birmingham, AL 35294, USA
Published online on: May 15, 2015 https://doi.org/10.3892/ijo.2015.3006
Pages: 269-279

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Primary cilia are microtubule-based organelles that regulate smoothened-dependent activation of the GLI transcription factors in canonical hedgehog signaling. In many cancers, primary cilia are markedly decreased or absent. The lack of primary cilia may inhibit or alter canonical hedgehog signaling and, thereby, interfere in the cellular responsiveness to modulators of smoothened activity. Clinical trials of smoothened antagonists for cancer treatment have shown the best response in basal cell carcinomas, with limited response in other solid tumors. To determine whether the presence or absence of primary cilia in cancer cells will predict their responsiveness to modulation of smoothened activity, we compared the ability of an agonist and/or inhibitor of smoothened (SAG and SANT1, respectively) to modulate GLI-mediated transcription, as measured by GLI1 mRNA level or GLI-luciferase reporter activity, in non-cancer cells with primary cilia (ovarian surface epithelial cells and breast fibroblasts), in cancer cells that cannot assemble primary cilia (MCF7, MDA-MB-231 cell lines), and in cancer cells with primary cilia (SKOV3, PANC1 cell lines). As expected, SAG and SANT1 resulted in appropriate modulation of GLI transcriptional activity in ciliated non-cancer cells, and failed to modulate GLI transcriptional activity in cancer cells without primary cilia. However, there was also no modulation of GLI transcriptional activity in either ciliated cancer cell line. SAG treatment of SKOV3 induced localization of smoothened to primary cilia, as assessed by immunofluorescence, even though there was no increase in GLI transcriptional activity, suggesting a defect in activation of SMO in the primary cilia or in steps later in the hedgehog pathway. In contrast to SKOV3, SAG treatment of PANC1 did not cause the localization of smoothened to primary cilia. Our data demonstrate that the presence of primary cilia in the cancer epithelial cells lines tested does not indicate their responsiveness to smoothened activation or inhibition.

View Figures

View References

1	Brechbiel J, Miller-Moslin K and Adjei AA: Crosstalk between hedgehog and other signaling pathways as a basis for combination therapies in cancer. Cancer Treat Rev. 40:750–759. 2014. View Article : Google Scholar : PubMed/NCBI
2	Xie J, Bartels CM, Barton SW and Gu D: Targeting hedgehog signaling in cancer: Research and clinical developments. Onco Targets Ther. 6:1425–1435. 2013. View Article : Google Scholar : PubMed/NCBI
3	Shen F, Cheng L, Douglas AE, Riobo NA and Manning DR: Smoothened is a fully competent activator of the heterotrimeric G protein G(i). Mol Pharmacol. 83:691–697. 2013. View Article : Google Scholar : PubMed/NCBI
4	Fernández-Zapico ME: Primers on molecular pathways GLI: More than just Hedgehog? Pancreatology. 8:227–229. 2008. View Article : Google Scholar : PubMed/NCBI
5	Stecca B and Ruiz I Altaba A: Context-dependent regulation of the GLI code in cancer by HEDGEHOG and non-HEDGEHOG signals. J Mol Cell Biol. 2:84–95. 2010. View Article : Google Scholar : PubMed/NCBI
6	Kasper M, Regl G, Frischauf AM and Aberger F: GLI transcription factors: Mediators of oncogenic Hedgehog signalling. Eur J Cancer. 42:437–445. 2006. View Article : Google Scholar : PubMed/NCBI
7	Lipinski RJ, Gipp JJ, Zhang J, Doles JD and Bushman W: Unique and complimentary activities of the Gli transcription factors in Hedgehog signaling. Exp Cell Res. 312:1925–1938. 2006. View Article : Google Scholar : PubMed/NCBI
8	Nozawa YI, Lin C and Chuang PT: Hedgehog signaling from the primary cilium to the nucleus: An emerging picture of ciliary localization, trafficking and transduction. Curr Opin Genet Dev. 23:429–437. 2013. View Article : Google Scholar : PubMed/NCBI
9	Briscoe J and Thérond PP: The mechanisms of Hedgehog signalling and its roles in development and disease. Nat Rev Mol Cell Biol. 14:416–429. 2013. View Article : Google Scholar : PubMed/NCBI
10	Hui CC and Angers S: Gli proteins in development and disease. Annu Rev Cell Dev Biol. 27:513–537. 2011. View Article : Google Scholar : PubMed/NCBI
11	Dennler S, André J, Alexaki I, Li A, Magnaldo T, ten Dijke P, Wang XJ, Verrecchia F and Mauviel A: Induction of sonic hedgehog mediators by transforming growth factor-beta: Smad3-dependent activation of Gli2 and Gli1 expression in vitro and in vivo. Cancer Res. 67:6981–6986. 2007. View Article : Google Scholar : PubMed/NCBI
12	Ji Z, Mei FC, Xie J and Cheng X: Oncogenic KRAS activates hedgehog signaling pathway in pancreatic cancer cells. J Biol Chem. 282:14048–14055. 2007. View Article : Google Scholar : PubMed/NCBI
13	Stecca B, Mas C, Clement V, Zbinden M, Correa R, Piguet V, Beermann F and Ruiz I Altaba A: Melanomas require HEDGEHOG-GLI signaling regulated by interactions between GLI1 and the RAS-MEK/AKT pathways. Proc Natl Acad Sci USA. 104:5895–5900. 2007. View Article : Google Scholar : PubMed/NCBI
14	Noubissi FK, Goswami S, Sanek NA, Kawakami K, Minamoto T, Moser A, Grinblat Y and Spiegelman VS: Wnt signaling stimulates transcriptional outcome of the Hedgehog pathway by stabilizing GLI1 mRNA. Cancer Res. 69:8572–8578. 2009. View Article : Google Scholar : PubMed/NCBI
15	Yoon JW, Gallant M, Lamm ML, Iannaccone S, Vieux KF, Proytcheva M, Hyjek E, Iannaccone P and Walterhouse D: Noncanonical regulation of the Hedgehog mediator GLI1 by c-MYC in Burkitt lymphoma. Mol Cancer Res. 11:604–615. 2013. View Article : Google Scholar : PubMed/NCBI
16	Pasca di Magliano M and Hebrok M: Hedgehog signalling in cancer formation and maintenance. Nat Rev Cancer. 3:903–911. 2003. View Article : Google Scholar
17	Kwon YJ, Hurst DR, Steg AD, Yuan K, Vaidya KS, Welch DR and Frost AR: Gli1 enhances migration and invasion via up-regulation of MMP-11 and promotes metastasis in ERα negative breast cancer cell lines. Clin Exp Metastasis. 28:437–449. 2011. View Article : Google Scholar : PubMed/NCBI
18	Abidi A: Hedgehog signaling pathway: a novel target for cancer therapy: vismodegib, a promising therapeutic option in treatment of basal cell carcinomas. Indian J Pharmacol. 46:3–12. 2014. View Article : Google Scholar : PubMed/NCBI
19	Sekulic A, Migden MR, Oro AE, Dirix L, Lewis KD, Hainsworth JD, Solomon JA, Yoo S, Arron ST, Friedlander PA, et al: Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 366:2171–2179. 2012. View Article : Google Scholar : PubMed/NCBI
20	Hassounah NB, Bunch TA and McDermott KM: Molecular pathways: The role of primary cilia in cancer progression and therapeutics with a focus on Hedgehog signaling. Clin Cancer Res. 18:2429–2435. 2012. View Article : Google Scholar : PubMed/NCBI
21	Han YG, Kim HJ, Dlugosz AA, Ellison DW, Gilbertson RJ and Alvarez-Buylla A: Dual and opposing roles of primary cilia in medulloblastoma development. Nat Med. 15:1062–1065. 2009. View Article : Google Scholar : PubMed/NCBI
22	Yuan K, Serra R and Frost AR: Primary cilia in the breast and breast cancer. Open Breast Cancer J. 2:101–107. 2010.
23	Sadlonova A, Novak Z, Johnson MR, Bowe DB, Gault SR, Page GP, Thottassery JV, Welch DR and Frost AR: Breast fibroblasts modulate epithelial cell proliferation in three-dimensional in vitro co-culture. Breast Cancer Res. 7:R46–R59. 2005. View Article : Google Scholar : PubMed/NCBI
24	Steg A, Wang W, Blanquicett C, Grunda JM, Eltoum IA, Wang K, Buchsbaum DJ, Vickers SM, Russo S, Diasio RB, et al: Multiple gene expression analyses in paraffin-embedded tissues by TaqMan low-density array: Application to hedgehog and Wnt pathway analysis in ovarian endometrioid adenocarcinoma. J Mol Diagn. 8:76–83. 2006. View Article : Google Scholar : PubMed/NCBI
25	Berbari NF, O’Connor AK, Haycraft CJ and Yoder BK: The primary cilium as a complex signaling center. Curr Biol. 19:R526–R535. 2009. View Article : Google Scholar : PubMed/NCBI
26	Yuan K, Frolova N, Xie Y, Wang D, Cook L, Kwon YJ, Steg AD, Serra R and Frost AR: Primary cilia are decreased in breast cancer: Analysis of a collection of human breast cancer cell lines and tissues. J Histochem Cytochem. 58:857–870. 2010. View Article : Google Scholar : PubMed/NCBI
27	Egeberg DL, Lethan M, Manguso R, Schneider L, Awan A, Jørgensen TS, Byskov AG, Pedersen LB and Christensen ST: Primary cilia and aberrant cell signaling in epithelial ovarian cancer. Cilia. 1:152012. View Article : Google Scholar
28	Menzl I, Lebeau L, Pandey R, Hassounah NB, Li FW, Nagle R, Weihs K and McDermott KM: Loss of primary cilia occurs early in breast cancer development. Cilia. 3:72014. View Article : Google Scholar : PubMed/NCBI
29	Nobutani K, Shimono Y, Yoshida M, Mizutani K, Minami A, Kono S, Mukohara T, Yamasaki T, Itoh T, Takao S, et al: Absence of primary cilia in cell cycle-arrested human breast cancer cells. Genes Cells. 19:141–152. 2014. View Article : Google Scholar
30	Kruk PA and Auersperg N: Human ovarian surface epithelial cells are capable of physically restructuring extracellular matrix. Am J Obstet Gynecol. 167:1437–1443. 1992. View Article : Google Scholar : PubMed/NCBI
31	Nielsen SK, Møllgård K, Clement CA, Veland IR, Awan A, Yoder BK, Novak I and Christensen ST: Characterization of primary cilia and Hedgehog signaling during development of the human pancreas and in human pancreatic duct cancer cell lines. Dev Dyn. 237:2039–2052. 2008. View Article : Google Scholar : PubMed/NCBI
32	Lewis MT and Veltmaat JM: Next stop, the twilight zone: Hedgehog network regulation of mammary gland development. J Mammary Gland Biol Neoplasia. 9:165–181. 2004. View Article : Google Scholar : PubMed/NCBI
33	Chen JK, Taipale J, Young KE, Maiti T and Beachy PA: Small molecule modulation of Smoothened activity. Proc Natl Acad Sci USA. 99:14071–14076. 2002. View Article : Google Scholar : PubMed/NCBI
34	Mukherjee S, Frolova N, Sadlonova A, Novak Z, Steg A, Page GP, Welch DR, Lobo-Ruppert SM, Ruppert JM, Johnson MR, et al: Hedgehog signaling and response to cyclopamine differ in epithelial and stromal cells in benign breast and breast cancer. Cancer Biol Ther. 5:674–683. 2006. View Article : Google Scholar : PubMed/NCBI
35	Zhang X, Harrington N, Moraes RC, Wu MF, Hilsenbeck SG and Lewis MT: Cyclopamine inhibition of human breast cancer cell growth independent of Smoothened (Smo). Breast Cancer Res Treat. 115:505–521. 2009. View Article : Google Scholar
36	Meyers-Needham M, Lewis JA, Gencer S, Sentelle RD, Saddoughi SA, Clarke CJ, Hannun YA, Norell H, da Palma TM, Nishimura M, et al: Off-target function of the Sonic hedgehog inhibitor cyclopamine in mediating apoptosis via nitric oxide-dependent neutral sphingomyelinase 2/ceramide induction. Mol Cancer Ther. 11:1092–1102. 2012. View Article : Google Scholar : PubMed/NCBI
37	Taipale J, Chen JK, Cooper MK, Wang B, Mann RK, Milenkovic L, Scott MP and Beachy PA: Effects of oncogenic mutations in Smoothened and Patched can be reversed by cyclopamine. Nature. 406:1005–1009. 2000. View Article : Google Scholar : PubMed/NCBI
38	Wang Y, Arvanites AC, Davidow L, Blanchard J, Lam K, Yoo JW, Coy S, Rubin LL and McMahon AP: Selective identification of hedgehog pathway antagonists by direct analysis of smoothened ciliary translocation. ACS Chem Biol. 7:1040–1048. 2012. View Article : Google Scholar : PubMed/NCBI
39	Kiprilov EN, Awan A, Desprat R, Velho M, Clement CA, Byskov AG, Andersen CY, Satir P, Bouhassira EE, Christensen ST, et al: Human embryonic stem cells in culture possess primary cilia with hedgehog signaling machinery. J Cell Biol. 180:897–904. 2008. View Article : Google Scholar : PubMed/NCBI
40	Wong SY, Seol AD, So PL, Ermilov AN, Bichakjian CK, Epstein EH Jr, Dlugosz AA and Reiter JF: Primary cilia can both mediate and suppress Hedgehog pathway-dependent tumorigenesis. Nat Med. 15:1055–1061. 2009. View Article : Google Scholar : PubMed/NCBI
41	Hassounah NB, Nagle R, Saboda K, Roe DJ, Dalkin BL and McDermott KM: Primary cilia are lost in preinvasive and invasive prostate cancer. PLoS One. 8:e685212013. View Article : Google Scholar : PubMed/NCBI
42	Emoto K, Masugi Y, Yamazaki K, Effendi K, Tsujikawa H, Tanabe M, Kitagawa Y and Sakamoto M: Presence of primary cilia in cancer cells correlates with prognosis of pancreatic ductal adenocarcinoma. Hum Pathol. 45:817–825. 2014. View Article : Google Scholar : PubMed/NCBI
43	LoRusso PM, Rudin CM, Reddy JC, Tibes R, Weiss GJ, Borad MJ, Hann CL, Brahmer JR, Chang I, Darbonne WC, et al: Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res. 17:2502–2511. 2011. View Article : Google Scholar : PubMed/NCBI
44	Amakye D, Jagani Z and Dorsch M: Unraveling the therapeutic potential of the Hedgehog pathway in cancer. Nat Med. 19:1410–1422. 2013. View Article : Google Scholar : PubMed/NCBI
45	Tang JY, Mackay-Wiggan JM, Aszterbaum M, Yauch RL, Lindgren J, Chang K, Coppola C, Chanana AM, Marji J, Bickers DR, et al: Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. N Engl J Med. 366:2180–2188. 2012. View Article : Google Scholar : PubMed/NCBI
46	Von Hoff DD, LoRusso PM, Rudin CM, Reddy JC, Yauch RL, Tibes R, Weiss GJ, Borad MJ, Hann CL, Brahmer JR, et al: Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med. 361:1164–1172. 2009. View Article : Google Scholar : PubMed/NCBI
47	Wang Y, Zhou Z, Walsh CT and McMahon AP: Selective translocation of intracellular Smoothened to the primary cilium in response to Hedgehog pathway modulation. Proc Natl Acad Sci USA. 106:2623–2628. 2009. View Article : Google Scholar : PubMed/NCBI
48	Barakat B, Yu L, Lo C, Vu D, De Luca E, Cain JE, Martelotto LG, Dedhar S, Sadler AJ, Wang D, et al: Interaction of smoothened with integrin-linked kinase in primary cilia mediates Hedgehog signalling. EMBO Rep. 14:837–844. 2013. View Article : Google Scholar : PubMed/NCBI
49	Tian H, Callahan CA, DuPree KJ, Darbonne WC, Ahn CP, Scales SJ and de Sauvage FJ: Hedgehog signaling is restricted to the stromal compartment during pancreatic carcinogenesis. Proc Natl Acad Sci USA. 106:4254–4259. 2009. View Article : Google Scholar : PubMed/NCBI
50	Yauch RL, Gould SE, Scales SJ, Tang T, Tian H, Ahn CP, Marshall D, Fu L, Januario T, Kallop D, et al: A paracrine requirement for hedgehog signalling in cancer. Nature. 455:406–410. 2008. View Article : Google Scholar : PubMed/NCBI
51	Feldmann G, Habbe N, Dhara S, Bisht S, Alvarez H, Fendrich V, Beaty R, Mullendore M, Karikari C, Bardeesy N, et al: Hedgehog inhibition prolongs survival in a genetically engineered mouse model of pancreatic cancer. Gut. 57:1420–1430. 2008. View Article : Google Scholar : PubMed/NCBI
52	Banerjee U and Hadden MK: Recent advances in the design of Hedgehog pathway inhibitors for the treatment of malignancies. Expert Opin Drug Discov. 9:751–771. 2014. View Article : Google Scholar : PubMed/NCBI
53	Lee JJ, Perera RM, Wang H, Wu DC, Liu XS, Han S, Fitamant J, Jones PD, Ghanta KS, Kawano S, et al: Stromal response to Hedgehog signaling restrains pancreatic cancer progression. Proc Natl Acad Sci USA. 111:E3091–E3100. 2014. View Article : Google Scholar : PubMed/NCBI
54	Epstein EH: Basal cell carcinomas: Attack of the hedgehog. Nat Rev Cancer. 8:743–754. 2008. View Article : Google Scholar : PubMed/NCBI
55	Chenna V, Hu C, Pramanik D, Aftab BT, Karikari C, Campbell NR, Hong SM, Zhao M, Rudek MA, Khan SR, et al: A polymeric nanoparticle encapsulated small-molecule inhibitor of Hedgehog signaling (NanoHHI) bypasses secondary mutational resistance to Smoothened antagonists. Mol Cancer Ther. 11:165–173. 2012. View Article : Google Scholar :
56	Lauth M, Bergström A, Shimokawa T and Toftgård R: Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists. Proc Natl Acad Sci USA. 104:8455–8460. 2007. View Article : Google Scholar : PubMed/NCBI